Table 1.

Summary of prostate cancer–associated SNPs discovered in GWAS and replicated in men of African descent

Geners numberPositionaImplicated in GWASReplication Study designDisease phenotypeRisk alleleAssociation test OR (95% CI)PReferenceCorrection for ancestry
3p12rs266075387,193,364Eeles et al., 2008 (10)Case–control (868 cases and 878 controls)Sporadic prostate cancerTOR (T allele) = 1.17 (1.02–1.35)0.029Xu et al., 2009 (11)Model adjusted for age, ancestry proportion, and study population
7p15.2 (JAZF1)rs1048656727,943,088Thomas et al., 2008 (12)Nested case–control (860 cases and 575 controls)Sporadic prostate cancerGOR (G allele) = 1.18 (1.00–1.40)Waters et al., 2009 (13)Models adjusted for age and proportion of European ancestry
Multicenter sample (2,899 cases and 2,538 controls)Sporadic prostate cancerCOR (C allele) = 1.18 (1.08–1.29)0.0002Chang et al., 2011 (14)Model adjusted for age and study center
8q24rs16901979128,194,098Gudmundsson et al., 2007 (15)Case–control (868 cases and 878 controls)Sporadic prostate cancerAOR (A allele) = 1.38 (1.19–1.60)1.7E-05Xu et al., 2009 (11)Model adjusted for age, ancestry proportion, and study population
Multicenter sample (2,642 cases and 2,584 controls)Sporadic prostate cancerAOR (A allele) = 1.39 (1.28–1.52)1.9 E-14Chang et al., 2011 (14)Model adjusted for age and study center
Hospital-based case–control (490 cases and 567 controls)Sporadic prostate cancerAOR (A allele) = 1.5 (1.1–2.2)0.008Robbins et al., 2007 (16)Model adjusted for age and global and local 8q24 ancestry
Community-based case–control (127 cases and 345 controls)Sporadic prostate cancerAOR (A allele) = 1.60 (1.17–2.19)0.003Wang et al., 2010 (17)Noneb
Case–control (338 cases and 426 controls)Sporadic prostate cancerAOR (A allele) = 1.41 (1.02–1.95)0.03Okobia et al, 2011 (18)None
Case–control (156 cases and 231 controls)Early onset prostate cancer (diagnosed among 65 years and younger)AOR (A allele) = 2.30 (1.40–3.77)0.001Okobia et al., 2011 (18)None
rs10086908128,081,119Al Olama et al., 2009 (19)Case–control (868 cases and 878 controls)Sporadic prostate cancerTOR (T allele) = 1.31 (1.11–1.55)1.1E-03Xu et al., 2009 (11)Model adjusted for age, ancestry proportion, and study population
Multicenter sample (861 cases and 876 controls)Sporadic prostate cancerTOR (T allele) = 1.31 (1.11–1.54)0.001Chang et al., 2011 (14)Model adjusted for age and study center
rs13254738128,173,525Ghoussaini et al., 2008 (20)Case–control (868 cases and 878 controls)Sporadic prostate cancerCOR (C allele) = 1.36 (1.17–1.58)4.9E-05Xu et al., 2009 (11)Model adjusted for age, ancestry proportion, and study population
Multicenter sample (2,557 cases and 2,277 controls)Sporadic prostate cancerCOR (C allele) = 1.29 (1.18–1.41)1.03 × 10−8Chang et al., 2011 (14)Model adjusted for age and study center
Nested case–control (1,614 cases and 837 controlsSporadic prostate cancerCOR (C allele) = 1.24 (1.09–1.42)Haiman et al., 2007 (21)Model adjusted for genome-wide European ancestry and study
rs6983561128,176,062Al Olama et al., 2009 (19)Case–control (868 cases and 878 controls)Sporadic prostate cancerCOR (C allele) = 1.31 (1.13–1.52)2.8E-04Xu et al., 2009 (11)Model adjusted for age, ancestry proportion, and study population
Multicenter sample (2,764 cases and 3,255 controls)Sporadic prostate cancerCOR (C allele) = 1.37 (1.27–1.49)3.5 E-15Chang et al., 2011 (14)Model adjusted for age and study center
Community-based case–control (127 cases and 345 controls)Sporadic prostate cancerCOR (C allele) = 1.55 (1.15–2.09)0.0039Wang et al., 2010 (17)Noneb
Nested case–control (1,614 cases and 837 controls)Sporadic prostate cancerCOR (C allele) = 1.34 (1.18–1.53)Haiman et al., 2007 (21)Model adjusted for genome-wide European ancestry and study
rs7000448128,510,352Ghoussaini et al., 2008 (20)Case–control (868 cases and 878 controls)Sporadic prostate cancerTOR (T allele) = 1.20 (1.03–1.40)0.016Xu et al., 2009 (11)Model adjusted for age, ancestry proportion, and study population
Multicenter sample (1,698 cases and 2,329 controls)Sporadic prostate cancerTOR (T allele) = 1.27 (1.15–1.41)3.0 E-6Chang et al., 2011 (14)Model adjusted for age and study center
Community-based case–control (127 cases and 345 controls)Sporadic prostate cancerTOR (T allele) = 1.41 (1.03–1.94)0.03Wang et al., 2010 (17)Noneb
Nested case–control (1,614 cases and 837 controls)Sporadic prostate cancerCOR (C allele) = 1.33 (1.12–1.58)Haiman et al., 2007 (21)Model adjusted for genome-wide European ancestry and study
rs6983267128,482,487Yeager et al., 2007 (22); Thomas et al., 2008 (12)Multicenter sample (3,666 cases and 2,992 controls)Sporadic prostate cancerGOR (G allele) = 1.32 (1.18–1.49)3.3 E-6Chang et al., 2011 (14)Model adjusted for age and study center
Population-based case study (417 cases and 925 Illumina controls)Sporadic prostate cancerTOR (T allele) = 0.6 (0.4–0.7)1.3 E-4Xu et al., 2010 (23)Model adjusted for proportion of West African ancestry
Nested case–control (1,614 cases and 837 controlsSporadic prostate cancerG1.43 (1.17–1.75)Haiman et al., 2007 (21)Model adjusted for genome-wide European ancestry and study
rs1447295128,554,220Amundadottir et al., 2006 (24)Multicenter sample (3,167 cases and 3,325 controls)Sporadic prostate cancerAOR (A allele) = 1.11 (1.02–1.21)0.014Chang et al., 2011 (14)Model adjusted for age and study center
Case–control (171 cases and 256 cases)Sporadic prostate cancer; diagnosed among men of 65 years and youngerAOR AA genotype = 2.63 (1.14–6.05)Schumacher et al., 2007 (25)None
rs10090154128,601,319Al Olama et al., 2009 (19)Multicenter sample (1,683 cases and 1,403 controls)Sporadic prostate cancerT1.20 (1.04–1.37)0.011Chang et al., 2011 (14)Model adjusted for age and study center
rs7017300128,594,450Eeles et al., 2008 (10)Population-based case study (417 cases and 925 Illumina controls)Sporadic prostate cancerCOR (C allele) = 1.2 (1.0–1.5)0.03Xu et al., 2010 (23)Model adjusted for proportion of West African ancestry
10q11.2 MSMBrs1099399451,219,502Eeles et al., 2008 (10)Multicenter sample (3,374 cases and 2,982 controls)Sporadic prostate cancerTOR (T allele) = 1.12 (1.03–1.21)0.005Chang et al., 2011 (14)Model adjusted for age and study center
11q13rs793134268,751,073Eeles et al., 2008 (10)Multicenter sample (2,445 cases and 2,018 controls)Sporadic prostate cancerGOR (G allele) = 1.15 (1.03–1.29)0.014Chang et al., 2011 (14)Model adjusted for age and study center
rs1089644968,751,243Thomas et al., 2008 (12)Multicenter sample (2,056 cases and 1,898 controls)Sporadic prostate cancerGOR (G allele) = 1.12 (1.01–1.24)0.031Chang et al., 2011 (14)Model adjusted for age and study center
Hospital-based case–control (454 cases and 301 controls)Sporadic prostate cancerAOR (A allele) = 0.7 (0.54–0.93)0.009Hooker et al., 2010 (26)Model adjusted for IA estimates from 100 AIMs; same SNP not associated with aggressive disease
17q12 (HNF1B)rs443079633,172,153Gudmundsson et al., 2007 (27)Hospital-based case–control study (364 cases and 353 controls)Sporadic prostate cancerTOR (T allele) = 1.26 (1.01–1.56)0.04Sun et al., 2008 (28)Nonec
Multicenter sample (3,112 cases and 2,911 controls)Sporadic prostate cancerTOR (T allele) = 1.08 (1.00–1.18)0.053Chang et al., 2011 (14)Model adjusted for age and study center
Hospital-based case–control (454 cases and 301 controls)Sporadic prostate cancerAOR (A allele) = 1.48 (1.11–1.96)0.008Hooker et al., 2010 (26)IA estimates from 100 AIMs; same SNP not associated with aggressive disease
Case–control (868 cases and 878 controls)Sporadic prostate cancerTOR (T allele) = 1.16 (1.00-1.34)0.056Xu et al., 2009 (11)Model adjusted for age, ancestry proportion, and study population
17q21 (ZNF652)rs721010044,791,748Haiman et al., 2011 (8)Original GWAS in AA menOR (per allele) = 1.513.4 × 10−13Adjusted for age and ancestry
17q24.3rs185996266,620,348Eeles et al., 2008 (10)Population-based case study (417 cases and 925 Illumina controls)Sporadic prostate cancerGOR (G Allele) = 1.2 (1.0–1.5)0.033Xu et al., 2010 (23)Model adjusted for proportion of West African ancestry
19q13.33 (KLK2 and KLK3)rs273583956,056,435Eeles et al., 2008 (10)Hospital-based case–control (454 cases and 301 controls)Sporadic prostate cancerAOR (A allele) = 0.78 (0.60–1.00)0.04Hooker et al., 2010 (26)Model adjusted for IA estimates from 100 AIMs; same SNP not associated with aggressive disease
Xp11.22 (NUDT10/11)rs594557251,246,423Gudmundsson et al., 2008 (29)Nested case–control (860 cases and 575 controls)Sporadic prostate cancerAOR (A allele) = 1.34 (1.05–1.71)Waters et al., 2009 (13)Models adjusted for age and proportion of European ancestry
Hospital-based case–control (454 cases and 301 controls)Sporadic prostate cancerA1.48 (1.01–2.16)0.05Hooker et al., 2010 (26)Model adjusted for IA estimates from 100 AIMs; same SNP not associated with aggressive disease
Multicenter sample (1,764 cases and 1,235 controls)Sporadic prostate cancerAOR (A allele) = 1.11 (1.02–1.20)0.02Chang et al., 2011 (14)Model adjusted for age and study center
rs594561951,258,412Eeles et al., 2008 (10)Multicenter sample (1,390 cases and 1,845 controls)Sporadic prostate cancerGOR (G allele) = 1.09 (1.00–1.18)0.039Chang et al., 2011 (14)Model adjusted for age and study center

Abbreviations: AA, African American; IA, individual ancestry; AIM, ancestry informative markers.

  • aPosition based on NCBI Build 36.

  • bStudy reports similar results found when adjusted for age and proportion of African ancestry.

  • cStudy reports similar results found when models adjusted for proportion of African ancestry.